Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double blind, placebo controlled study
Azpiroz F, Dubray C, Bernalier-Donadille A, Cardot JM, Accarino A, Serra J, Wagner A, Respondek F, Dapoigny M
Published in Neurogastroenterology & Motility
Methodology
Randomized double-blind placebo-controlled trial of 5 g/day short-chain FOS for 4 weeks in patients with IBS.
Key Findings
scFOS increased faecal Bifidobacteria and reduced anxiety scores, but did not significantly improve overall IBS symptom severity versus placebo.
Conclusions
Short-chain FOS is well tolerated in IBS and modifies microbiota, with limited symptomatic benefit.
Limitations
Small sample, 4-week duration, single prebiotic dose.
Supplements Studied
Short-chain FOS increased faecal bifidobacteria and reduced anxiety scores without significantly improving overall IBS symptom severity.
Outcomes Measured
Short-chain FOS increased faecal bifidobacteria in patients with irritable bowel syndrome.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.